Oral Micronized Progesterone vs Prometrium: Switching Between Them

They Are the Same Drug

Oral micronized progesterone (OMP) is the United States Pharmacopeia (USP) name for the active pharmaceutical ingredient inside Prometrium capsules. Prometrium, manufactured by AbbVie (formerly Solvay), received FDA approval in 1998 as the first oral micronized progesterone product for hormone therapy. Every generic labeled "micronized progesterone capsules, USP" contains the same molecule produced through the same micronization process that reduces particle size to increase intestinal absorption 1.

The confusion stems from how clinicians and pharmacies reference the drug. A prescription written for "Prometrium 200 mg" and one written for "micronized progesterone 200 mg" direct the pharmacist to dispense the same therapeutic agent. The FDA's Orange Book rates approved generics as "AB" therapeutically equivalent to Prometrium, meaning they meet bioequivalence standards within the 80-125% confidence interval for both area under the curve (AUC) and peak concentration (Cmax) 2.

So why do patients notice differences? The answer sits in the inactive ingredients.

Excipient Differences That Matter Clinically

The most clinically relevant distinction between Prometrium and its generics is the oil base. Prometrium suspends micronized progesterone in peanut oil (arachis oil). This creates a real contraindication for patients with peanut allergy 3.

Several generic manufacturers use sunflower oil, sesame oil, or other vegetable oil bases. For the estimated 2.2% of US adults with peanut allergy reported by FARE (Food Allergy Research and Education), generic formulations offer the only oral micronized progesterone option 4.

Beyond the oil base, differences include:

• Gelatin capsule composition (bovine vs. plant-based in some generics)
• Dye agents (Prometrium uses FD&C Yellow No. 6 in the 200 mg capsule)
• Lecithin source variations
• Glycerin concentrations

These inactive ingredient variations can affect capsule dissolution timing. A 2019 pharmacokinetic study comparing three generic progesterone formulations found all met FDA bioequivalence criteria, but individual patient Cmax values varied by up to 18% between products when tested in the same subjects 5. For most women, this variance produces no perceptible clinical difference. For patients sensitive to progesterone's neurosteroid metabolite allopregnanolone (which causes the sedation and mood effects), even modest absorption-rate changes can shift side-effect intensity.

The PEPI Trial: Establishing OMP's Role in HRT

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, published in JAMA in 1995 (N=875), established oral micronized progesterone as a viable alternative to medroxyprogesterone acetate (MPA) for endometrial protection during estrogen therapy. Women randomized to conjugated equine estrogens (CEE) 0.625 mg plus cyclic micronized progesterone 200 mg for 12 days per month had a 0% rate of endometrial hyperplasia at 36 months 1.

The trial also demonstrated a lipid advantage. OMP preserved the HDL-cholesterol increase produced by estrogen alone, while MPA blunted it by approximately 50%. This finding shifted prescribing patterns toward micronized progesterone in cardiovascular-conscious HRT regimens.

Both Prometrium and its generics contain the identical micronized progesterone used in PEPI. No head-to-head trial has compared brand Prometrium against a generic version for endometrial outcomes because, pharmacologically, there is no mechanistic reason to expect a difference in a bioequivalent product.

When and Why Patients Switch

Patients transition between brand and generic micronized progesterone for several reasons. Cost ranks first. Brand Prometrium without insurance can exceed $300 for a 30-day supply of 200 mg capsules, while generics range from $15 to $80 depending on pharmacy and manufacturer 6.

Insurance formulary changes trigger involuntary switches. A patient stable on Prometrium for years may receive a generic substitution when her plan removes brand coverage. Conversely, patients on a generic that gets discontinued by its manufacturer (a common event in the generic hormone market) may need to switch to another generic or to brand.

Allergy-driven switches occur when a patient newly diagnosed with peanut sensitivity must move off Prometrium specifically. The reverse also happens: patients on a sesame-oil-based generic who develop sesame allergy (now a top-9 allergen recognized by FASTER Act 2021) may need a different formulation 7.

How to Switch Safely

Switching between bioequivalent oral micronized progesterone products does not require dose adjustment, washout periods, or bridging therapy. The active molecule is identical. A direct 1:1 transition (200 mg brand to 200 mg generic, or vice versa) on the next scheduled dose is standard practice.

Steps clinicians follow:

1. Confirm allergy status. Check for peanut, sesame, soy, and gelatin sensitivities before selecting the target product.
2. Verify bioequivalence rating. The replacement must carry an "AB" rating in the FDA Orange Book relative to Prometrium 2.
3. Maintain timing. OMP is taken at bedtime because its allopregnanolone metabolite produces significant sedation. Switching products should not change administration timing.
4. Schedule a 4-to-6 week check. Although the drugs are bioequivalent on a population level, individual patients may notice altered sedation intensity, breakthrough bleeding patterns, or GI tolerance changes due to excipient differences.
5. Document the manufacturer. Record the specific generic manufacturer (Teva, Mylan/Viatris, Sun Pharma, etc.) so that if the patient reports problems, the dispensing product is identifiable.

The Endocrine Society's 2022 position on bioidentical hormones confirms that FDA-approved micronized progesterone products, whether brand or generic, provide reliable endometrial protection when dosed appropriately 8.

Absorption and the Food Effect

Both Prometrium and generics show a significant food effect. Taking micronized progesterone with a high-fat meal increases Cmax by approximately 3-to-7-fold compared to fasting administration. The FDA-approved labeling for Prometrium specifies dosing "at bedtime" partly to standardize this variable (most patients have eaten dinner hours before bed, creating a moderate-absorption state) 3.

When switching products, the food-effect magnitude may differ slightly between oil bases. Peanut oil and sunflower oil have different fatty acid profiles that could theoretically alter micelle formation in the duodenum. In practice, this effect is absorbed within the FDA's bioequivalence window, but patients who switch and simultaneously change their evening eating habits may attribute perceived differences to the new product rather than to altered food timing.

Clinical instruction: advise patients switching formulations to keep their bedtime routine and pre-dose meal timing consistent for the first 6 weeks.

Sedation and Neurosteroid Differences Between Formulations

Progesterone's primary active metabolite, allopregnanolone, is a potent positive allosteric modulator of GABA-A receptors. This mechanism produces the drowsiness that makes bedtime dosing advantageous and daytime dosing impractical for most patients 9.

The rate of progesterone absorption directly influences peak allopregnanolone concentrations. A faster-dissolving capsule produces a sharper Cmax, a higher allopregnanolone spike, and more intense (but shorter-duration) sedation. A slower-dissolving capsule creates a flatter curve with less peak sedation but potentially more sustained overnight levels.

Patients switching from brand to a specific generic (or between generics) sometimes report that one "knocks them out" more intensely or that another leaves them feeling less rested despite adequate sleep. These reports are pharmacokinetically plausible even within bioequivalence bounds, because the 80-125% Cmax window permits a 45% range in peak drug levels between any two qualifying products.

For patients sensitive to these differences, requesting a specific generic manufacturer via "DAW-0" (dispense as written) coding or specifying the manufacturer on the prescription can maintain consistency across refills.

Endometrial Protection: Does the Brand Matter?

No published evidence demonstrates any difference in endometrial protection between brand Prometrium and AB-rated generics at equivalent doses. The PEPI trial's endometrial outcomes were achieved with the micronized progesterone molecule itself, not with any brand-specific formulation characteristic 1.

The North American Menopause Society (NAMS) 2022 position statement on hormone therapy does not distinguish between brand and generic micronized progesterone in its recommendations for endometrial protection during estrogen therapy. The recommended regimens (200 mg cyclically for 12-14 days per month, or 100 mg continuously) apply regardless of manufacturer 10.

Ultrasound monitoring of endometrial thickness remains the standard safety check for any woman on combined HRT. Switching progesterone products does not alter the monitoring schedule, which typically involves transvaginal ultrasound if breakthrough bleeding occurs or at annual well-woman visits per clinician preference.

Cost and Insurance Navigation

The pricing gap between brand and generic micronized progesterone is substantial. Average wholesale prices as of 2025:

• Prometrium 200 mg (brand): $9-$11 per capsule
• Generic micronized progesterone 200 mg: $0.50-$2.50 per capsule

For a standard 12-day cyclic regimen, that translates to roughly $108-$132 monthly for brand vs. $6-$30 for generic. Continuous daily dosing at 100 mg shows similar ratios 6.

Most commercial insurers and Medicare Part D plans cover generic micronized progesterone at Tier 1 (preferred generic) with copays of $0-$15. Brand Prometrium, if covered, typically sits at Tier 3 (non-preferred brand) with copays of $40-$80 or requires prior authorization documenting generic failure or allergy.

Patients who need brand specifically (peanut allergy requiring avoidance of specific generics, or documented intolerance to a generic excipient) can often obtain brand coverage through a formulary exception request supported by physician documentation of medical necessity.

Compounded Progesterone: A Different Category Entirely

Some patients ask about switching from FDA-approved OMP (brand or generic) to compounded progesterone capsules from specialty pharmacies. This is a fundamentally different clinical decision than switching between AB-rated products.

Compounded progesterone is not FDA-approved, does not undergo bioequivalence testing, and has shown significant dose variability in independent analyses. A 2001 FDA survey of compounded hormone products found that 34% of tested samples failed potency specifications 11.

The Endocrine Society, NAMS, and ACOG all recommend FDA-approved micronized progesterone over compounded alternatives for endometrial protection. Switching from an FDA-approved product to a compounded version introduces dosing uncertainty that can compromise uterine safety 8.

If a patient cannot tolerate any FDA-approved oral formulation due to excipient allergies, vaginal micronized progesterone (Endometrin, Crinone) or the levonorgestrel IUD represent alternatives with established endometrial protection data rather than compounded oral products.

Monitoring After a Switch

The 4-to-6 week post-switch assessment focuses on three domains:

Bleeding pattern. Any new breakthrough bleeding within 8 weeks of switching should be documented. In most cases, it reflects adjustment to slightly different absorption kinetics and resolves spontaneously. Persistent bleeding beyond 8 weeks warrants endometrial evaluation per standard guidelines 10.

Sleep and mood. Because allopregnanolone levels may shift subtly between products, patients should report changes in sleep onset latency, overnight waking, morning grogginess, or mood stability. These are dose-response phenomena. If a new generic produces more sedation, splitting the dose (100 mg at dinner, 100 mg at bed) can flatten the curve.

GI tolerance. Nausea, bloating, and abdominal discomfort vary with oil base and capsule dissolution characteristics. Patients who tolerated peanut-oil-based Prometrium for years may notice different GI patterns with a sunflower-oil generic. Taking the capsule with a small snack (100-200 calories containing some fat) often resolves new-onset GI symptoms.

If symptoms persist beyond 6 weeks and meaningfully affect quality of life, trialing a different generic manufacturer or reverting to the prior product is appropriate. Document the problematic manufacturer's NDC number for future avoidance.

Special Populations

Patients with peanut allergy: Must avoid brand Prometrium. Confirm the specific generic's oil base with the dispensing pharmacy before filling. Not all generics are peanut-free.

Patients on concurrent CNS depressants: The sedation interaction between progesterone's allopregnanolone and benzodiazepines, Z-drugs, or gabapentinoids may shift perceptibly when switching to a product with different Cmax timing. Warn patients on these combinations to assess sedation carefully during the first week after switching.

Patients using progesterone for luteal support in fertility treatment: Switching products mid-cycle during an active fertility treatment is discouraged. Complete the cycle on the current product, then switch for the next cycle if needed.

Transgender women on progesterone: Limited evidence guides progesterone use in transfeminine HRT. For those prescribed it, the same brand-vs-generic principles apply. The Endocrine Society's 2017 transgender guidelines do not recommend progesterone routinely but acknowledge its use in practice 12.